Head-to-head evidence
Beclomethasone dipropionate/formoterol fumarate/glycopyrrolate vs fluticasone furoate/umeclidinium/vilanterol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination) · full Asthma pipeline
Beclomethasone dipropionate/formoterol fumarate/glycopyrrolate
Marketed by Chiesi Farmaceutici
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2028 · NCT07282886 (registry estimate)
fluticasone furoate/umeclidinium/vilanterol · Trelegy Ellipta
Marketed by GlaxoSmithKline
NCT02924688 · Phase 3 · completed
This was a large (N=2,436) randomized, triple-blind, active-controlled Phase III trial comparing four fixed-dose combinations of fluticasone furoate/umeclidinium/vilanterol against two fluticasone furoate/vilanterol dual therapy controls in patients with inadequately controlled asthma. The primary endpoint, change from baseline in trough FEV1 at Week 24, was met for every pre-specified triple-therapy versus dual-therapy comparison, with all four least-squares mean differences favoring triple therapy and p<0.001. The combination of randomization, blinding, an active comparator, a large sample, a hard clinical endpoint, and a statistically significant primary result constitutes strong evidence.
Next expected readout: January 2027 · NCT05757102 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Beclomethasone dipropionate/formoterol fumarate/glycopyrrolate's landscape · fluticasone furoate/umeclidinium/vilanterol's landscape